Tempus AI Launches Preview Tool for Early Cancer Insights Within 24 Hours

Tempus has introduced "Preview," an AI-powered tool that provides early cancer insights within one day of sample receipt, aiming to bridge the time gap between diagnostic order and definitive genomic profiling results. The tool focuses on high-impact biomarkers where early insights can be critical for treatment planning.

At launch, Tempus Preview will surface patients more likely to harbor microsatellite instability (MSI-H) in colorectal, endometrial, prostate, and esophagogastric cancers, predict EGFR mutations in non-small cell lung cancer (NSCLC), and highlight increased probability of potential rare FGFR fusions in hepatobiliary and bladder cancers. The biomarker predictions are powered by Paige Predict, an advanced AI model that analyzes standard H&E images to provide genomic insights.

The introduction of this tool arrives as experts emphasize the importance of early and comprehensive biomarker testing in early-stage EGFR-mutated NSCLC. Early identification of EGFR mutations enables timely and appropriate therapy selection, supports multidisciplinary coordination, and helps avoid missed opportunities for optimal care. Integrating biomarker testing early in the treatment pathway is essential for personalizing therapy and improving patient outcomes.

Tempus Preview’s biomarker predictions are validated for clinical use as part of Tempus’ laboratory-developed test. The founder and CEO of Tempus stated that the company's unique combination of a diagnostic lab and an advanced data platform enables the building of AI models powered by real-world data, delivering early, clinically relevant information within one day of sample receipt.